Dr. Professor Pan Jing

• Professor Pan Jing is an Associate Professor in the Department of Hemato-Oncology and Immunotherapy, with more than 12 years of clinical experience in haematology.
• She is a recognised pioneer in CAR-T cell immunotherapy, particularly in the stratified treatment of leukaemia.
• Professor Pan has made significant contributions to advancing CAR-T strategies for both B-cell and T-cell acute lymphoblastic leukaemia, including optimising the management of CAR-T-related complications and establishing comprehensive post-treatment efficacy monitoring systems.
• In 2017, she pioneered stratified CAR-T treatment for B-ALL, followed by the introduction of the global donor CD7 CAR-T strategy for relapsed and refractory T-ALL/LBL in 2019.
• Professor Pan’s research has been published in leading international journals, including The Lancet Oncology, Blood, Leukaemia, Nature Medicine, JCO, and JHO.
• She is an active contributor to global immunotherapy research forums and has presented major scientific advancements at prestigious conferences, including ASCO, ASH, EHA, and JSH.
• Alongside research, she remains deeply involved in clinical care and translational research within a department comprising 80 beds, driving innovation in leukaemia immunotherapy.

Conditions treated byProfessor Pan Jing

• Acute Lymphoblastic Leukaemia (ALL)
• B-cell Acute Lymphoblastic Leukaemia (B-ALL)
• T-cell Acute Lymphoblastic Leukaemia (T-ALL)
• Lymphoblastic Lymphoma (LBL)
• Relapsed and Refractory Leukaemia

Area of Interest

• Leukaemia CAR-T Cell Immunotherapy
• Translational research in hematologic malignancies
• CD19 CAR-T therapy
• CD22 CAR-T therapy
• CD19-22 sequential CAR-T therapy
• CD7 CAR-T and CD5 CAR-T therapies
• Optimisation of CAR-T strategies for refractory and relapsed leukaemia